Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility

M.F. Costello, M.L. Misso, A. Balen, J. Boyle, L. Devoto, R.M. Garad, R. Hart, L. Johnson, C. Jordan, R.S. Legro, R.J. Norman, E. Mocanu, J. Qiao, R.J. Rodgers, L. Rombauts, E.C. Tassone, S. Thangaratnam, E. Vanky, and H.J. Teede

School of Women’s and Children’s Health, University of New South Wales, High St, Kensington, Sydney, New South Wales 2052, Australia
Monash Centre for Health Research and Implementation, Monash Public Health and Preventive Medicine, Monash University, Clayton, Victoria 3168, Australia
Monash Health, Clayton, Melbourne, Australia
Reproductive Medicine and Surgery, Leeds Centre for Reproductive Medicine, Leeds Teaching Hospitals, Leeds LS14 6LU, UK
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Chile, Santiago, 8320000, Chile
National Health and Medical Research Council Centre for Research Excellence in PCOS, Monash Centre for Health Research and Implementation, Monash Public Health and Preventive Medicine, Monash University, Victoria 3168, Australia
Division of Obstetrics and Gynaecology, University of Western Australia, Crawley, WA 6008, Australia
Victorian Assisted Reproductive Treatment Authority, Victoria 3000, Australia
Geneva Hollywood Fertility, 190 Cambridge St, Wembley WA 6014, Australia
Department of Obstetrics and Gynecology, Penn State University College of Medicine, H103, RM C3604, USA
National Health and Medical Research Council Centre for Research Excellence in PCOS, Monash University, Clayton, Melbourne, Australia
Division of Obstetrics and Gynaecology, Northern Health, Victoria 3040, Australia
Royal College of Surgeons, Rotunda Hospital, 123 St Stephen’s Green, Dublin D02 YN77, Ireland
Peking University Third Hospital, Haidian Qu, Beijing Shi 100083, China
Robinson Research Institute, University of Adelaide and Fertility SA, Adelaide, South Australia 5005, Australia
Royal College of Surgeons, Rotunda Hospital, 123 St Stephen’s Green, Dublin D02 YN77, Ireland
Peking University Third Hospital, Haidian Qu, Beijing Shi 100083, China
Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AD, UK
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim NO-7491, Norway

*Correspondence address. 41 Kanooka Grove, Clayton, Melbourne, Victoria 3168, Australia. E-mail: helena.teede@monash.edu © orcid.org/0000-0001-7609-577X

Submitted on September 9, 2018; editorial decision on October 3, 2018; accepted on December 13, 2018

STUDY QUESTION: What is the recommended assessment and management of infertile women with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise and consumer preference?

SUMMARY ANSWER: International evidence-based guidelines, including 44 recommendations and practice points, addressed prioritized questions to promote consistent, evidence-based care and improve the experience and health outcomes of infertile women with PCOS.

WHAT IS KNOWN ALREADY: Previous guidelines on PCOS lacked rigorous evidence-based processes, failed to engage consumer and multidisciplinary perspectives or were outdated. The assessment and management of infertile women with PCOS are inconsistent. The needs of women with PCOS are not being adequately met and evidence practice gaps persist.
**PARTICIPANTS/MATERIALS, SETTING, METHODS:** Governance included a six continent international advisory and a project board, a multidisciplinary international guideline development group (GDG), consumer and translation committees. Extensive health professional and consumer engagement informed the guideline scope and priorities. The engaged international society-nominated panel included endocrinology, gynaecology, reproductive endocrinology, obstetrics, public health and other experts, alongside consumers, project management, evidence synthesis and translation experts. Thirty-seven societies and organizations covering 71 countries engaged in the process. Extensive online communication and two face-to-face meetings over 15 months addressed 19 prioritized clinical questions involving nine evidence-based reviews and 10 narrative reviews. Evidence-based recommendations (EBRs) were formulated prior to consensus voting within the guideline panel.

**STUDY DESIGN, SIZE, DURATION:** International evidence-based guideline development engaged professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. A (AGREE) II-compliant processes were followed, with extensive evidence synthesis. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, desirable and undesirable consequences, feasibility, acceptability, cost, implementation and ultimately recommendation strength. The guideline was peer-reviewed by special interest groups across our partner and collaborating societies and consumer organizations, was independently assessed against AGREE II criteria and underwent methodological review. This guideline was approved by all members of the GDG and has been approved by the NHMRC.

**MAIN RESULTS AND THE ROLE OF CHANCE:** The quality of evidence (QOE) for the EBRs in the assessment and management of infertility in PCOS included very low \( (n = 1) \), low \( (n = 9) \) and moderate \( (n = 4) \) quality with no EBRs based on high-quality evidence. The guideline provides 14 EBRs, 10 clinical consensus recommendations (CCRs) and 20 clinical practice points on the assessment and management of infertility in PCOS. Key changes in this guideline include emphasizing evidence-based fertility therapy, including cheaper and safer fertility management.

**LIMITATIONS, REASONS FOR CAUTION:** Overall evidence is generally of low to moderate quality, requiring significantly greater research in this neglected, yet common condition. Regional health systems vary and a process for adaptation of this guideline is provided.

**WIDER IMPLICATIONS OF THE FINDINGS:** The international guideline for the assessment and management of infertility in PCOS provides clinicians with clear advice on best practice based on the best available evidence, expert multidisciplinary input and consumer preferences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation program supports the guideline with an integrated evaluation program.

**STUDY FUNDING/COMPETING INTEREST(S):** The guideline was primarily funded by the Australian National Health and Medical Research Council of Australia (NHMRC) supported by a partnership with ESHRE and the American Society for Reproductive Medicine (ASRM). GDG members did not receive payment. Travel expenses were covered by the sponsoring organizations. Disclosures of conflicts of interest were declared at the outset and updated throughout the guideline process, aligned with NHMRC guideline processes. Dr Costello has declared shares in Virtus Health and past sponsorship from Merck Serono for conference presentations. Prof. Norman has declared a minor shareholder interest in the IVF unit Fertility SA, travel support from Merck and grants from Ferring. Prof. Norman also has scientific advisory board duties for Ferring. The remaining authors have no conflicts of interest to declare.

This article was not externally peer-reviewed by Human Reproduction Open.

**Key words:** polycystic ovary syndrome / infertility / guideline / evidence-based / assessment / management / GRADE

**WHAT DOES THIS MEAN FOR PATIENTS?**

This guideline aims to optimize evidence-based, consistent care that meets the needs and improves the quality of life of infertile women with polycystic ovary syndrome (PCOS). The guideline and translation program were developed with full consumer participation at all stages, targeting areas and outcomes of priority for women with PCOS. The overall aim is to support women and their healthcare providers to optimize the assessment and management of infertility in PCOS. There is an emphasis on partnership in care and empowerment of women with PCOS. Personal characteristics, preferences, culture and values are considered. With effective translation, the guideline and suite of health professional and consumer resources will address the gaps and priorities identified by women with PCOS.
Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting reproductive aged women, with a prevalence of between 8% and 13% depending on the population studied and definitions used. PCOS is complex with reproductive, metabolic and psychological features (Teede et al., 2010). Infertility is a prevalent presenting feature of PCOS with ~75% of these women suffering infertility due to anovulation, making PCOS by far the most common cause of anovulatory infertility (Homburg, 2004).

The treatment of infertility in PCOS includes lifestyle changes (diet and exercise), pharmacological therapies (oral agents such as clomiphene citrate, letrozole or metformin or injectable agents such as gonadotrophins), surgical therapy (laparoscopic ovarian surgery) or IVF (Costello et al., 2012). IVM has been proposed to offer a promising alternative to conventional IVF (Chian, 2004).

Current guidelines on PCOS either are limited in breadth, do not follow rigorous best practice in development, have not involved consumers or are outdated (Teede et al., 2011; Legro et al., 2013; Conway et al., 2014; Goodman et al., 2015; Balen et al., 2016) resulting in inconsistent guidance for clinicians and women alike. To address these identified gaps, the first ever international evidence-based guideline for the assessment and management of PCOS was recently published and it integrates the best available evidence with international, multidisciplinary clinical expertise and consumer preferences in order to provide health professionals, consumers and policy makers with guidance (International Evidence-Based Guidelines for the Assessment and Management of Polycystic Ovary Syndrome, 2018; Teede et al., 2018a,b,c). This current paper is restricted to the section of the guideline addressing the assessment and management of infertility in PCOS. The clinical context and evidence informing the infertility section of the guideline are published in the full guideline (International Evidence-Based Guidelines for the Assessment and Management of Polycystic Ovary Syndrome, 2018).

Materials and Methods

Best practice evidence-based guideline development methodology was applied and are detailed in the full guideline (International Evidence-Based Guidelines for the Assessment and Management of Polycystic Ovary Syndrome, 2018). In short, the international evidence-based guideline development engaged health professional societies and consumer organizations, with multidisciplinary experts and women with PCOS directly involved at all stages.

A six continent international advisory and a project board, a multidisciplinary international guideline development group (GDG), plus consumer and translation committees provided governance. The engaged international society-nominated panel provided experts in endocrinology, gynaecology, reproductive endocrinology, obstetrics and public health, alongside consumers, project management, evidence synthesis and translation experts. Thirty-seven societies and organizations representing 71 countries were engaged in a 15-month process that addressed 19 prioritized clinical questions encompassing 9 evidence-based reviews and 10 narrative reviews. Appraisal of Guidelines for Research and Evaluation (AGREE) II-compliant processes were followed, with extensive evidence synthesis. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework was applied across evidence quality, desirable and undesirable consequences, feasibility, acceptability, cost, implementation and, ultimately, recommendation strength. Evidence-based recommendations (EBRs) were formulated prior to consensus voting within the guideline panel.

Interpreting the recommendations

The category of the recommendations includes evidence-based or consensus recommendations and has accompanying relevant clinical practice points (CPP), as described in Table I. When sufficient evidence was available in PCOS, an EBR was made, where there was insufficient evidence in PCOS, evidence in general or other relevant populations was also considered and if appropriate and there was consensus, the GDG made clinical consensus recommendations (CCRs). CPP highlighted important clinical and implementation issues arising from GDG consideration of evidence-based or CCR and from peer review.

The recommendation terms include ‘should’, ‘could’ and ‘should not’. These terms are informed by the nature of the recommendation (evidence or consensus), the GRADE framework and evidence quality and are independent descriptors reflecting the judgement of the multidisciplinary GDG including consumers. They refer to overall interpretation and practical application of the recommendation, balancing benefits and harms. ‘Should’ is used where benefits of the recommendation exceed harms, and where the recommendation can be trusted to guide practice. ‘Could’ is used where either the QOE was limited or the available studies demonstrate little clear advantage of one approach over another, or the balance of benefits to harm was unclear. ‘Should not’ is used where there is either a lack of appropriate evidence, or the harms may outweigh the benefits.

The GRADE of the recommendation is determined by the GDG from structured consideration of the GRADE framework (National Health and Medical Research Council, 2009) including desirable effects, undesirable effects, balance of effects, resource requirements and cost effectiveness, equity, acceptability and feasibility, and includes: *Conditional recommendation against the option; **Conditional recommendation for either the option or the comparison; ***Conditional recommendation for the option; **** Strong recommendation for the option. QOE is categorized (see Table II) according to:

- information about the number and design of studies addressing the outcome;
- judgments about the quality of the studies and/or synthesized evidence, such as risk of bias, inconsistency, indirectness, imprecision and any other considerations that may influence the QOE: key statistical data;
- and classification of the importance of the outcomes.

The QOE reflects the extent to which our confidence in an estimate of the effect is adequate to support a particular recommendation (National Health and Medical Research Council, 2009) and was largely determined by the expert evidence synthesis team.

Table I Categories of the polycystic ovary syndrome guideline recommendations.

| EBR     | Evidence-based recommendations: evidence sufficient to inform a recommendation made by GDG. |
|---------|---------------------------------------------------------------------------------------------|
| CCR     | Clinical consensus recommendations: in the absence of evidence, a clinical consensus recommendation has been made by the GDG. |
| CPP     | Clinical practice points: evidence not sought. A practice point has been made by the GDG where important issues arose from discussion of evidence-based or clinical consensus recommendations. |

GDG: the guideline development group (Teede et al., 2018a,b,c).
GRADE note that QOE is a continuum; any discrete categorization involves a degree of arbitrariness. Nevertheless, advantages of simplicity, transparency, and vividness outweigh these limitations (National Health and Medical Research Council, 2009). CCR are not rated in QOE (as no evidence was found) (see below) and CPP do not have a ‘GRADE’ rating as CPPs arose from discussion of evidence-based or CCR (Table I). The meaning or interpretation of the GRADE of recommendations according to strength (strong or conditional [or weak]) can be seen in Table III.

### Table II Quality (certainty) of evidence categories adapted from the grading of recommendations, assessment, development and evaluation frameworka.

| Quality   | Symbol  | Description                                                                 |
|-----------|---------|-----------------------------------------------------------------------------|
| High      | ★★★★   | Very confident that the true effect lies close to that of the estimate of the effect |
| Moderate  | ★★★    | Moderate confidence in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different |
| Low       | ★★      | Limited confidence in the effect estimate: the true effect may be substantially different from the estimate of the effect |
| Very Low  | ★       | Very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect |

| Source     | Teede et al. (2018a,b,c). |

aAdapted from the grading of recommendations, assessment, development, and evaluation framework (GRADE) (National Health and Medical Research Council 2009)

### Results

The guideline section addressing the assessment and management of infertile women with PCOS includes 14 EBRs, 10 CCR and 20 CPP. The QOE for the EBRs included very low (n = 1), low (n = 9), and moderate (n = 4) quality, with no EBRs based on high-quality evidence. The GRADE of recommendations included the following: *Conditional recommendation against the option (n = 2, all CCRs); **Conditional recommendation for either the option or the comparison (n = 1, a CCR); ***Conditional recommendation for the option (n = 15, 11 EBRs and four CCRs); and **** Strong recommendation for the option (n = 3, all EBRs).

The recommendations for the assessment and treatment of infertility can be found in the full guideline (International Evidence-Based Guidelines for the Assessment and Management of Polycystic Ovary Syndrome, 2018). The comprehensive evidence reviews, profiles and GRADE frameworks supporting each recommendation, can be found in the supplementary Technical report (2018) at https://www.monash.edu/__data/assets/pdf_file/0020/1412282/PCOS-Guideline_Technical-report.pdf. A summary of the recommendations for the assessment and treatment of infertility can be seen in Fig. 1

### Tubal patency testing

#### Clinical question

Should women with PCOS and infertility due to anovulation alone with normal semen analysis have tubal patency testing prior to starting ovulation induction with timed intercourse or IUI treatment or delayed tubal patency testing?

#### Table III Interpretation of the strength of the GRADE of recommendations according to consumers, health professionals and policy makers.

| Target group   | Strong recommendationsa | Conditional (weak) recommendations for the option (test or treatment) | Conditional (weak) recommendation for either the option or the comparison | CPPb |
|----------------|-------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------------|------|
| Consumers      | Most people in your situation would want the recommended course of action and only a small proportion would not. | The majority of people in your situation would want the recommended course of action, but some would not. | There is considerable lack of clarity over whether the majority of people in your situation would want the recommended course of action or not. | Clinicians, patients and policy makers are informed on the clinical implications relevant to implementation of recommendations. |
| Health Professionals | Most patients should receive the recommended course of action. | Recognize that different choices will be appropriate for different patients and that greater effort is needed with individuals to arrive at management decisions consistent with values and preferences. Decision aids and shared decision making are important here. | Policy making needs to consider perspectives and involvement of diverse stakeholders. | Policy decisions remain unclear. |
| Policy makers  | The recommendation can be adopted as policy in most situations. | | |

aStrong recommendations based on high-quality evidence will apply to most patients for whom these recommendations are made, but they may not apply to all patients in all conditions; no recommendation can take into account all of the often-compelling unique features of individual patients and clinical circumstances.

bA CPP is developed by the GDG to support recommendations. Advice can be provided to enhance shared decision making, and on factors to be considered in implementing a specific test or intervention.
Algorithm 5: Assessment and treatment of infertility

1st line non-pharmacological management for infertility

Lifestyle interventions

1st line pharmacological management for infertility

Letrozole
(consider Letrozole as 1st line therapy)

Clomiphene citrate

Clomiphene citrate + metformin

Metformin

2nd line pharmacological/surgical management

Gonadotrophins

Laparoscopic ovarian surgery

3rd line management could be other appropriate interventions including IVF

Off label prescribing: Letrozole, COCPs, metformin and other pharmacological treatments are generally off label in PCOS, as pharmaceutical companies have not applied for approval in PCOS. However, off label use is predominantly evidence-based and is allowed in many countries. Where it is allowed, health professionals should inform women and discuss the evidence, possible concerns and side effects of treatment.

Evidence summary and recommendations on PCOS management

Assessment and treatment of infertility

Assessment of factors that may affect fertility, treatment response or pregnancy outcomes

Factors such as blood glucose, weight, blood pressure, smoking, alcohol, diet, exercise, sleep and mental, emotional and sexual health should be optimised in women with PCOS, to improve reproductive and obstetric outcomes, aligned with recommendations in the general population. Refer to the International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018 available at: www.monash.edu/medicine/sphpm/mchri/pcos

Monitoring during pregnancy is important for women with PCOS, given increased risk of adverse maternal and offspring outcomes.

For women with PCOS and infertility due to anovulation alone with normal semen analysis, the risks, benefits, costs and timing of tubal patency testing should be discussed on an individual basis.

Tubal patency testing should be considered prior to ovulation induction for women with PCOS where there is suspected tubal infertility.

Ovulation induction principles

The use of ovulation induction agents, including letrozole, metformin and clomiphene citrate is off label in many countries'.

Pregnancy should be excluded prior to ovulation induction.

Unsuccessful, prolonged use of ovulation induction agents should be avoided, due to poor success rates.

Letrozole

Letrozole should be considered first line pharmacological treatment for ovulation induction in women with PCOS with anovulatory infertility and no other infertility factors to improve ovulation, pregnancy and live birth rates.

Where letrozole is not available or use is not permitted or cost is prohibitive, health professionals should use other ovulation induction agents.

Health professionals and women should be aware that the risk of multiple pregnancy appears to be less with letrozole, compared to clomiphene citrate.

Clomiphene citrate and metformin

Clomiphene citrate could be used alone in women with PCOS with anovulatory infertility and no other infertility factors to improve ovulation and pregnancy rates.

Metformin could be used alone in women with PCOS, with anovulatory infertility and no other infertility factors, to improve ovulation, pregnancy and live birth rates, although women should be informed that there are more effective ovulation induction agents.

Clomiphene citrate could be used in preference, when considering clomiphene citrate or metformin for ovulation induction in women with PCOS who are obese (BMI ≥ 30 kg/m²) with anovulatory infertility and no other infertility factors.

If metformin is being used for ovulation induction in women with PCOS who are obese (BMI ≥ 30kg/m²) with anovulatory infertility and no other infertility factors, clomiphene citrate could be added to improve ovulation, pregnancy and live birth rates.

Clomiphene citrate could be combined with metformin, rather than persisting with clomiphene citrate alone, in women with PCOS who are clomiphene citrate-resistant, with anovulatory infertility and no other infertility factors, to improve ovulation and pregnancy rates.

The risk of multiple pregnancy is increased with clomiphene citrate use and therefore monitoring needs to be considered.

Figure 1 Practitioner support tool Algorithm 1: Screening, diagnostic assessment risk assessment and lifestage. ©International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2018, Helena Teede et al. Monash University (monash.edu/medicine/sphpm/mchri/pcos), 2018, by permission of Monash University, on behalf of the NHMRC Centre for Research Excellence in PCOS. This image/content is not covered by the terms of the Creative Commons licence of this publication. For permission to reuse, please contact the rights holder.
Clinical need for the question

One of the leading causes of female infertility is tubal pathology, potentially affecting around 30% of infertile women (Al Subhi et al., 2013). The diagnostic assessment of infertility often includes tubal testing by hysterosalpingography or laparoscopy as outlined in the World Health Organization (WHO) evidence report on infertility management in PCOS. PCOS is the most frequent cause of anovulation in infertile women and ovulation induction is the most common treatment, however, there is little information about the prevalence of tubal pathology or the need for IUI with normal semen analysis in infertile women with PCOS.

Summary of narrative evidence

A systematic review was not conducted to answer this question and this was reviewed narratively based on clinical expertise. There is no evidence to support that hydrosalpinges or other Fallopian tube disorders are more frequent in PCOS women (Broeze et al., 2011). Yet the assessment of tubal patency is considered in infertility workup, as outlined in the WHO evidence report on infertility treatment in PCOS. Whilst adverse effects from this intervention are not common, false positives have been described and tubal patency testing may be more appropriate when targeted to those at increased risk of tubal infertility.
In this context, consideration of risks for tubal pathology are clinically appropriate including: previous abdominal or pelvic sepsis, previous pelvic and/or abdominal surgery, cases of recurrent acute pelvic pain (Luttjeboer et al., 2009), history of sexual transmitted diseases or pelvic inflammatory disease, or endometriosis.
Justification
If the patient has a clinical history of factors associated with tubal infertility, it was deemed that hysterosalpingography could be considered, consistent with routine assessment of infertility. Hysterosalpingography requires dilation of the cervix that generally produces some discomfort, false positives are described and other related complications are uncommon. A lack of evidence to guide practice was noted in PCOS when considering these recommendations, however general population approaches were judged as applicable in this population, where other risk factors are present.

Ovulation induction principles
In reviewing the literature on pharmacological treatment for ovulation induction, general principles emerged that apply across all recommendations. These have been extracted into a set of CPP to inform women and guide health professionals when considering or recommending pharmacological therapy for ovulation induction in PCOS. These practice points apply to all pharmacological treatments prioritized and addressed in the guidelines. In addition, duration of ovulation induction was considered under general principles.

Letrozole
Clinical question
In women with PCOS, are aromatase inhibitors (AI) effective for improving fertility outcomes?

Clinical need for the question
AIs are effective as ovulation-inducing agents, including letrozole and anastrozole, with letrozole being the most widely used (Mitwally and Casper, 2001; Elzur and Tulandi, 2008). These agents prevent the aromatase-induced conversion of androgens to oestrogens, including in the ovary. Yet their mechanisms of ovulation induction are unknown, however they increase the secretion of FSH thereby stimulating ovarian follicle development and maturation (Adashi, 1984). The efficacy, adverse effects and overall role of letrozole in oral ovulation induction have remained controversial.

Summary of systematic review evidence
AI versus placebo. One small RCT (Kamath et al., 2010) with a low risk of bias compared letrozole to placebo in women with clomiphene citrate-resistant PCOS and found that letrozole was better than placebo for ovulation rate per patient (Letrozole: 6 patients/18 patients (33.33%), Placebo: 0 patients/18 patients (0%), P = 0.006) but there was no difference between letrozole and placebo for pregnancy rate per patient or live birth rate per patient. It is important to note that the findings from this study are of low certainty due to serious risk of imprecision. This study was included in a meta-analysis by Frank et al. (2014) and Misso et al. (2012), however since there is only one study, the meta-analyses do not provide additional evidence.

AI versus clomiphene citrate. Thirteen RCTs compared letrozole with clomiphene citrate. Seven of these RCTs had a high risk of bias (Atay et al., 2006; Zeinalzadeh et al., 2010; Sheikh-El-Arab Elsedeek and Elmaghraby, 2011; Banerjee Ray et al., 2012; Kar, 2012; Nazik and Kuntepe, 2012; Selim and Borg, 2012), two had a moderate risk of bias (Begum et al., 2009; Dehbashi et al., 2009) and four had a low risk of bias (Bayar et al., 2006; Badawy et al., 2009; Roy et al., 2012; Legro et al., 2014a,b). Upon meta-analysis, we found that letrozole was better than clomiphene citrate for ovulation rate per patient, pregnancy rate per patient and live birth rate per patient. There was no difference between letrozole and clomiphene citrate for multiple pregnancy rate per patient and miscarriage rate per patient. When subgroup analysis was conducted for studies that included women with PCOS who were therapy naive, there was no difference between the two interventions for any outcome although we note that for pregnancy rate per patient the odds ratio (OR) 1.68 [95% CI 0.96, 2.94] had an I² of 0% and a P value of 0.07.

AI versus clomiphene citrate + metformin. One RCT with moderate risk of bias found that there is no statistical difference between letrozole and clomiphene citrate plus metformin for ovulation rate per cycle, pregnancy rate per cycle, miscarriage rate per pregnancy and multiple pregnancy rate per pregnancy in clomiphene citrate-resistant women with PCOS (Abu Hashim et al., 2010b). This study was included in a meta-analysis by Frank et al. (2014) and Misso et al. (2012), however since there is only one study, the meta-analysis does not provide additional evidence.

AI versus laparoscopic ovarian surgery. Three RCTs with low risk of bias (Abu Hashim et al., 2010a, Abdellah, 2011; Ibrahim et al., 2017) compared letrozole to laparoscopic ovarian surgery and found that there was insufficient evidence of a difference between letrozole and laparoscopic ovarian surgery. One of the RCTs in 147 women with clomiphene citrate resistance found that letrozole was better than laparoscopic ovarian surgery for ovulation rate per cycle (Abdellah, 2011), however the evidence is of low certainty. The systematic review by Farquhar et al. (2012) combined these studies in meta-analysis for pregnancy rate per patient, multiple pregnancy rate per pregnancy and miscarriage rate per pregnancy, and there was no statistical difference between the two interventions.

Summary of narrative review evidence
Aromatase catalyses the conversion of androgens to oestrogens, including in the ovary, and increase FSH secretion (Adashi, 1984), stimulating ovarian follicle development and maturation. Als prevent this conversion. These agents were originally used to improve pregnancy rates and limit adverse effects (Casper, 2003; Healey et al., 2003), especially with clomiphene resistance and failure (Imani et al., 1999; Imani et al., 2002 January, Casper, 2003; Legro et al., 2007). Letrozole has side-effects include gastrointestinal disturbances, hot flushes, headache and back pain (Holzer et al., 2006; Legro et al., 2014a,b) and concerns have been raised in an abstract on potential teratogenic effects (Bijian et al., 2005), which are as yet unconfirmed in peer-reviewed publications, yet this has sparked a series of warnings to avoid use of Al in infertility. Multiple subsequent case series (Tulandi et al., 2006; Forman et al., 2007; Dehbashi et al., 2009; Sharma et al., 2014; Tatsumi et al., 2017), multi-centre RCTs (Legro et al., 2014a,b; Diamond et al., 2015) and a recent systematic review and meta-analysis (Wang et al., 2017), all failed to note an increased congenital anomaly rate, with prevalence of anomalies with letrozole or clomiphene under 5% (the expected anomaly rate in this population is 5–8%) (Davies et al., 2012). Whilst use of letrozole is evidence-
based, patient explanation and consent is appropriate as letrozole therapy for infertility is off label.

**Justification**

Women with PCOS are significantly more likely both to ovulate and to have a live birth after use of letrozole compared to clomiphene, the previous first-line agent. The likelihood of live birth is increased 40–60% with letrozole compared to clomiphene. Similarly, failure to ovulate (letrozole resistance) is lower with letrozole versus clomiphene. Multiple pregnancy rates appear lower with letrozole than clomiphene. Hot flushes, generally the least desired side effect of any anti-oestrogen, are less common with letrozole than clomiphene, but still present, while fatigue and dizziness are more common with letrozole. The balance of benefits in terms of improved live births with letrozole and less hot flushes was considered to currently outweigh the adverse effects of relatively increased fatigue and dizziness, multiple pregnancy, and unconfirmed concerns about higher congenital anomalies.

**Letrozole and Clomiphene**

**Clomiphene citrate and/or metformin**

**Clinical questions**

1. In women with PCOS, is clomiphene citrate effective for improving fertility outcomes?
2. In women with PCOS, is metformin effective for improving fertility outcomes?
3. In women with PCOS and a BMI > 30–32 kg/m², what is the effectiveness of metformin compared to clomiphene citrate for improving fertility outcomes?

**Clinical need for the questions**

Clomiphene citrate is a selective oestrogen receptor modulator with both oestrogenic and anti-oestrogenic properties (Shelly et al., 2008). It was first approved for use in women with anovulation in 1967 (Pritts, 2010) and acts as an anti-oestrogen (Adashi, 1984). Clomiphene citrate resistance and failure is well documented (Palomba et al., 2009a) and a discrepancy is noted between good ovulation rates and lower pregnancy rates due to the anti-oestrogenic effects of clomiphene citrate on the endometrium and cervical mucus. Rates of twin pregnancy and triplets with clomiphene citrate are 5–7% and 0.3%, respectively, and ovarian hyperstimulation syndrome (OHSS) is less than 1% (Kafy and Tulandi, 2007). The potential for borderline increased risk of ovarian tumours with 12 cycles or more has been noted (R ossing et al., 1994).

Insulin resistance is common in PCOS (Dunaif et al., 1989; DeUgarte et al., 2005), driving ovarian androgen biosynthesis and increased bioavailability of free androgens. Excess local ovarian androgen production augmented by hyperinsulinaemia causes premature follicular atresia and anovulation (Costello and Eden, 2003). This has led to insulin-sensitizing drugs use in ovulation induction. Metformin has been most widely studied in PCOS and has the most reassuring safety profile (Palomba et al., 2009b). Efficacy has been controversial and therapeutic regimens are not well standardized in clinical practice, with variable doses in use (Hoeger et al., 2008).

**Summary of systematic review evidence**

**Metformin versus placebo.** One systematic review (Morley et al., 2017) with up to 14 studies and one RCT (Kjosted et al., 2011) were identified to address this comparison. Metformin was better than placebo for live birth rate per participant, pregnancy rate per participant and ovulation rate per participant. Pregnancy rate and ovulation rate remained statistically significantly better than placebo when subgrouped by BMI (BMI < 30 kg/m² and BMI > 30 or 32 kg/m² subgroups); however, live birth rate lost statistical significance when subgrouped by BMI. There was no statistically significant difference between metformin and placebo for miscarriage rate per pregnancy (including when subgrouped). Gastrointestinal upsets were statistically significantly lower with placebo than metformin (including when subgrouped). Multiple pregnancy and OHSS were not reported in the systematic review. It is important to note that the findings for live birth rate and miscarriage rate are of low certainty due to serious risk of bias and serious risk of imprecision in the body of evidence; and findings for pregnancy rate, ovulation rate and adverse events are of moderate certainty due to serious risk of bias. Risk of bias appraisals and GRADE assessments have been adopted from previous versions of this guideline (Balen et al., 2016).

In an RCT of 149 participants, with moderate certainty, there were no statistically significant differences between metformin and placebo for pregnancy rate per participant, multiple pregnancy rate per pregnancy or miscarriage rate per pregnancy. The majority of the trials stopped metformin at diagnosis of pregnancy or at week 12. Note: insufficient evidence of a differential effect of metformin on BMI.

**Clomiphene citrate versus placebo.** One high-quality systematic review with low risk of bias found that clomiphene citrate was better than placebo for pregnancy rate per participant and ovulation rate per participant, however the evidence was of very low certainty due to very serious risk of bias and imprecision (Brown and Farquhar, 2016).

**Metformin versus clomiphene citrate.** One systematic review (Morley et al., 2017) with up to seven studies was identified to address this comparison. There were no statistically significant differences between metformin and clomiphene for live birth rate per pregnancy, multiple pregnancy per pregnancy, miscarriage rate per pregnancy, pregnancy rate or ovulation rate. When subgrouped by BMI, clomiphene citrate was better than metformin for live birth rate, pregnancy rate and ovulation rate in BMI > 30 kg/m²; and metformin was better than clomiphene citrate for pregnancy rate in BMI < 30 kg/m². Adverse events and OHSS were not reported in the systematic review. It is important to note that the findings for live birth rate, multiple pregnancy rate and pregnancy rate are of very low certainty due to very serious risk of bias, serious risk of imprecision and for live birth rate, also serious risk of inconsistency; findings for miscarriage rate and ovulation rate are of low certainty due to serious risk of bias and serious risk of imprecision in the body of evidence.

**Metformin versus metformin + clomiphene citrate.** One high-quality systematic review with low risk of bias evaluating two RCTs with a mean BMI ≥ 30 kg/m² (Palomba et al., 2009c) and two RCTs (one medium quality RCT with moderate risk of bias (Johnson et al., 2010) and one low-quality RCT with high risk of bias (Karimzadeh and Javedani, 2010)) were identified by the search. Metformin plus clomiphene citrate was better than metformin alone for ovulation rate, pregnancy rate and live birth rate. There was no statistically significant...
difference between metformin plus clomiphene citrate and metformin alone for miscarriage rate or adverse events.

**Clomiphene citrate versus metformin + clomiphene citrate.** One systematic review (Morley et al., 2017) with up to 21 studies, and one RCT (Maged et al., 2015) were identified to address this comparison. Metformin plus clomiphene citrate was statistically significantly better than clomiphene citrate alone for pregnancy rate per participant and ovulation rate per participant, including when subgrouped by BMI (BMI < 30 kg/m² and BMI > 30 kg/m² subgroups). Adverse events were statistically significantly fewer with clomiphene citrate alone than with metformin plus clomiphene citrate. There was no statistically significant difference between metformin plus clomiphene citrate and clomiphene citrate alone for live birth rate per pregnancy, multiple pregnancy rate per pregnancy or miscarriage rate per pregnancy. OHSS was not reported in the systematic review. It is important to note that the findings for live birth rate, multiple pregnancy and miscarriage rate are of low certainty due to serious risk of bias and serious risk of imprecision in the body of evidence; and findings for pregnancy rate, ovulation rate and adverse events are of moderate certainty due to serious risk of bias. The additional RCT (Maged et al., 2015) was insufficient evidence to supplement the findings of Morley et al. (2017).

**Clomiphene citrate versus AI (letrozole).** Thirteen RCTs (level II) compared letrozole with clomiphene citrate. Seven of these RCTs had a high risk of bias (Atay et al., 2006; Zeinalzadeh et al., 2010; Sheikh-El-Arab Elsedeek and Elmaghraby, 2011; Banerjee Ray et al., 2012; Kar, 2012; Nazik and Kumtepe, 2012; Selim and Borg, 2012), two had a moderate risk of bias (Begum et al., 2009; Dehbashi et al., 2009) and four had a low risk of bias (Bayar et al., 2006; Badawy et al., 2009; Roy et al., 2012; Legro et al., 2014a,b). Upon meta-analysis, we found that letrozole was better than clomiphene citrate for ovulation rate per patient (Atay et al., 2006; Begum et al., 2009; Dehbashi et al., 2009; Sheikh-El-Arab Elsedeek and Elmaghraby, 2011; Banerjee Ray et al., 2012; Nazik and Kumtepe, 2012; Roy et al., 2012; Legro et al., 2014a,b); pregnancy rate per patient (Atay et al., 2006; Bayar et al., 2006; Badawy et al., 2009; Begum et al., 2009; Dehbashi et al., 2009; Zeinalzadeh et al., 2010; Sheikh-El-Arab Elsedeek and Elmaghraby, 2011; Banerjee Ray et al., 2012; Kar, 2012; Nazik and Kumtepe, 2012; Roy et al., 2012; Selim and Borg, 2012; Legro et al., 2014a,b); and per cycle (Nazik and Kumtepe, 2012; Roy et al., 2012; Selim and Borg, 2012) and live birth rate per patient (Bayar et al., 2006; Dehbashi et al., 2009; Banerjee Ray et al., 2012; Roy et al., 2012; Legro et al., 2014a,b). There was no difference between letrozole and clomiphene citrate for ovulation rate per cycle (Bayar et al., 2006; Badawy et al., 2009; Nazik and Kumtepe, 2012; Roy et al., 2012; Selim and Borg, 2012); multiple pregnancy rate per patient (Atay et al., 2006; Badawy et al., 2009; Dehbashi et al., 2009; Zeinalzadeh et al., 2010; Kar, 2012; Nazik and Kumtepe, 2012; Roy et al., 2012; Legro et al., 2014a,b) and miscarriage rate per patient (Bayar et al., 2006; Badawy et al., 2009; Begum et al., 2009; Dehbashi et al., 2009; Banerjee Ray et al., 2012; Kar, 2012; Nazik and Kumtepe, 2012; Roy et al., 2012; Legro et al., 2014a,b). When subgroup analysis was conducted for studies that included women with PCOS who were therapy naive, there was no difference between the two interventions for any outcome, though we note that for pregnancy rate per patient the OR 1.68 [95% CI 0.96, 2.94] had an \( I^2 \) of 0% and a \( P \) value of 0.07.

**Clomiphene citrate versus gonadotrophin (FSH).** Two RCTs were identified by the search to address this comparison. One RCT with low-quality and high risk of bias (Lopez et al., 2004) compared recombinant FSH with clomiphene citrate in women with PCOS who were therapy naive and found that there was no difference between the two interventions for all fertility outcomes. The second was a multi-centre RCT with moderate risk of bias (Homburg et al., 2012) comparing clomiphene citrate with low-dose gonadotrophins, as the first line therapy for ovulation induction in anovulatory women with PCOS who were therapy naive. They reported with per protocol analysis that the clinical pregnancy rate was significantly higher in the gonadotrophin treated group. Furthermore, the chance of pregnancy was almost double in the first treatment cycle when compared to clomiphene citrate. Brown and Farquhar (2016) meta-analysed these same two RCTs combining data for live birth rate and ongoing pregnancy rate and found that gonadotrophins were better than clomiphene citrate (OR 0.64 [0.41, 0.98] \( P = 0.041, I^2 = 0\% \)). Meta-analysis of the two studies for clinical pregnancy rate found that clomiphene citrate was better than gonadotrophins (OR 0.61 [0.40, 0.93] \( P = 0.021, I^2 = 0\% \)). It is important to be cautious of these results (using per protocol event rates), as the number of participants randomized has been used as the denominator when the denominator should have been the number of participants per protocol.

**Clomiphene citrate versus clomiphene citrate + gonadotrophin (FSH).** Two RCTs were identified to address this comparison, however there was insufficient evidence to determine whether one intervention was better than the other (Mukherjee et al., 2010; Abu Hashim et al., 2012).

**Justification**

Clomiphene citrate therapy requires specialist care. Costs to the patient of monitoring (tests and specialist visits) and accessibility to specialist care may present barriers, however increased costs will be offset by reduced multiple pregnancies. Metformin is low cost, accessible and can be used alone and/or in combination with clomiphene citrate, given efficacy on systematic review. Usual doses of metformin range from 1500 mg (most commonly) to 1700 mg per day for non-fertility studies. A change in usual care may result in more likely to prescribe metformin. Metformin may be associated with mild gastrointestinal related adverse events (see Chapter 4 of full guideline document). Whilst use is evidence-based, patient explanation and consent is appropriate as metformin therapy for infertility is off label.

**Gonadotrophins**

**Clinical question**

In women with PCOS, are gonadotrophins effective for improving fertility outcomes?

**Clinical need for the question**

Gonadotrophin therapy is used clinically in women with anovulatory PCOS who have been treated with other first line ovulation induction agents if they have failed to ovulate or if the responses reduce chances of conception (e.g. persistent hypersecretion of LH, or an anti-oestrogenic endometrial effects). To prevent overstimulation and
multiple pregnancy, the traditional standard step-up regimens (Lunenfeld and Insler, 1974) were replaced by either low-dose step-up regimens (Hamilton-Fairley et al., 1991; White et al., 1996) or step-down regimens (van Santbrink et al., 1995) with gonadotrophins used alone and different gonadotrophic preparations appearing to work equally well (Nugent et al., 2000). It can be difficult to predict stimulation responses in PCOS and to achieve a single dominant follicle to reduce multiple pregnancy and OHSS, and careful monitoring of follicular development by ultrasound is required with triggers only used with two or less follicles over 14 mm. The efficacy, safety and role of gonadotrophins compared to other alternatives, including single or combined oral ovulation induction agents or laparoscopic surgery, remains unclear.

Summary of systematic review evidence

**Gonadotrophin (FSH) versus clomiphene citrate.** Two RCTs were identified by the search to address this comparison. One RCT with low quality and a high risk of bias (Lopez et al., 2004) compared recombinant FSH with clomiphene citrate in women with PCOS who were therapy naïve and found that there was no difference between the two interventions for all fertility outcomes. The second was a multi-centre RCT with moderate risk of bias (Homburg et al., 2012) comparing clomiphene citrate with low-dose gonadotrophins as the first line therapy for ovulation induction in anovulatory women with PCOS who were therapy naïve. They reported with per protocol analysis that the clinical pregnancy rate was significantly higher in the gonadotrophin treated group. Furthermore, the chance of pregnancy was almost double in the first treatment cycle when compared to clomiphene citrate. Brown and Farquhar (2016) meta-analysed these same two RCTs combining data for live birth rate and ongoing pregnancy rate and found that gonadotrophins were better than clomiphene citrate (OR 0.64 [0.41, 0.98] P = 0.041, I²=0%). Meta-analysis of the two studies for clinical pregnancy rate found that clomiphene citrate was better than gonadotrophins (OR 0.61 [0.40, 0.93] P = 0.021, I²=0%). It is important to be cautious of these results (using per protocol event rates), as the number of participants randomized has been used as the denominator when the denominator should have been the number of participants per protocol.

**Gonadotrophins versus clomiphene citrate + metformin.** Two RCTs compared FSH with clomiphene citrate plus metformin (Abu Hashim, et al. 2011a,b, Begum et al., 2013). The RCTs found that FSH was better than clomiphene citrate plus metformin for ovulation rate per participant and pregnancy rate per participant. There was no statistical difference between the two interventions for live birth rate per participant, multiple pregnancy rate per pregnancy, OHSS, miscarriage rate per pregnancy or gastrointestinal side-effects or adverse events. A systematic review by Abu Hashim et al. (2015) conducted a meta-analysis including RCTs comparing gonadotrophins versus clomiphene citrate combined with metformin in clomiphene resistant PCOS women that do not meet our PICO (P—patient, problem or population; I—intervention; C—comparison, control or comparator; O—outcome), however some sensitivity analysis was conducted with the two RCTs listed below. A sensitivity analysis for ovulation rate in 263 patients demonstrated that gonadotrophins are better for ovulation rate (OR 0.13; 95% CI 0.07–0.25; P < 0.00001, I² = 7%); but there was no statistically significant difference between the two interventions for multiple pregnancy rate (n = 263, OR 0.33; 95% CI 0.06–1.68, P = 0.18, heterogeneity not reported). This meta-analysis, which the GDG considered to be clinically relevant, demonstrated a significantly higher ovulation, clinical pregnancy and ongoing pregnancy/live birth rate with gonadotrophins compared to clomiphene citrate plus metformin in clomiphene resistant PCOS women.

**Gonadotrophins versus gonadotrophins + metformin.** One RCT with moderate risk of bias found that FSH plus metformin was better than FSH alone for live birth rate per participant, ovulation rate per participant and pregnancy rate per participant (Begum et al., 2013). There was no statistical difference between the two interventions for multiple pregnancy rate per pregnancy, miscarriage rate per pregnancy or adverse events.

A Cochrane review evaluating the use of metformin as an adjunct to gonadotrophin ovulation induction in PCOS (Bordewijk et al., 2017) was identified by the search, however it included studies that did not meet the selection criteria for this question. The GDG considered the meta-analyses in the Cochrane review as clinically relevant. The meta-analysis demonstrated a statistically significantly higher ongoing pregnancy, clinical pregnancy and live birth rate with no statistically significant difference in multiple pregnancy, miscarriage or OHSS rates when metformin is combined with gonadotrophins in clomiphene citrate-resistant PCOS women.

**Gonadotrophins versus laparoscopic ovarian surgery.** One high-quality systematic review of RCTs (Level I) with low risk of bias compared laparoscopic ovarian surgery to gonadotrophins and found that there was no difference between the interventions for live birth rate per patient and pregnancy rate per patient, ovulation rate per patient and miscarriage rate per pregnancy, but laparoscopic ovarian surgery had a lower multiple pregnancy rate (OR 0.13 [0.03–0.59] I² = 0%, four studies, 303 participants) (Farquhar et al., 2012) compared to gonadotrophins.

**Gonadotrophins versus gonadotrophins + clomiphene citrate.** One RCT (Ghanem et al., 2013) with moderate risk of bias found that FSH plus clomiphene citrate was better than FSH alone for ovulation rate per woman randomized and per protocol, total FSH dose used per woman randomized and per protocol, and duration of stimulation per woman randomized and per protocol. There was no statistical difference between the two interventions for pregnancy rate and live birth rate per woman randomized and per protocol.

**Justification.**

Gonadotrophin therapy is suitable for improving infertility in women with PCOS in specialist care, with close monitoring. Gonadotrophin therapy provides better per cycle and cumulative pregnancy and live birth rates compared with the use of oral anti-oestrogens and/or no therapy in anovulatory women with PCOS; and there is no evidence of teratogenicity. It is important to note that gonadotrophin therapy requires daily injections and the need for intensive monitoring with ultrasound; with a risk of multiple pregnancy, OHSS and increased cost of medication compared with oral agents.
Anti-obesity agents

Clinical question
In women with PCOS, are anti-obesity pharmacological agents effective for improving fertility outcomes?

Clinical need for the question
A 2017-systematic review and meta-analysis (Domecq et al., 2013) found that lifestyle interventions benefitted weight loss and natural pregnancy rate, with limited evidence for live birth rate or birthweight, yet natural birth rate did increase (Kiddy et al., 1992; Clark et al., 1995). Hence, the impact of non-pharmacological lifestyle interventions on live birth rates remains controversial. Engagement and adherence in lifestyle interventions are challenging. There is a need to assess other weight loss methods, such as pharmacological agents commenced in the pre-conception period, with some evidence they can induce weight loss and improve fertility outcomes in PCOS.

Summary of systematic review evidence
We did not identify any evidence in women with PCOS to answer the question and therefore the literature has been reviewed narratively.

Summary of narrative evidence
A randomized trial (that did not meet the inclusion criteria for this systematic review due to a change in interventions and combination of treatments) evaluated pre-conception treatment in women with PCOS: with lifestyle weight loss intervention incorporating caloric restriction, increased physical activity and pharmacological agent (initially sibutramine, and then orlistat); oral contraceptive pill; combined lifestyle and contraceptive pill on fertility outcomes (Legro et al., 2015). The trial randomized 149 women, and was stopped prematurely due to supposed futility with a low likelihood of showing a clinically meaningful difference. Given the small sample size in a three-arm trial, with no control group, no meaningful conclusions can be inferred. Within the lifestyle arm, including anti-obesity agents, there was a significant reduction in weight from baseline (−6.2Kg, 95% CI −07.1 to −5.3), and compared to the women on a combined oral contraception pill pre-conception, those on lifestyle with anti-obesity agents showed no differences in pregnancy outcomes. Evidence for these agents in other relevant population groups is lacking.

Justification
With inadequate evidence in both PCOS and infertility generally, the risk/benefit ratio is currently too uncertain to advocate anti-obesity pharmacological agents as a fertility treatment and it was deemed that it should remain an experimental treatment for this indication.

Laparoscopic ovarian surgery

Clinical question
In women with PCOS, is ovarian surgery effective for improving fertility outcomes?

Clinical need for the question
Observations that women with PCOS resumed regular ovulation following ovarian biopsies led to the development of surgical wedge resection via laparotomy (Stein, 1964). Observational data looked promising, but surgery was surpassed by ovulation induction agents until less invasive laparoscopic surgery was developed (Gjønnæss, 1984), with potential for fewer adhesions and lower cost. Minor methodological variations are reported (electrocautery, laser vaporization, multiple ovarian biopsies and others), all seemingly with effects on the endocrine profile. OHSS and multiple pregnancy risks are lower than with other options, but other risks potentially are higher, and clarification of the role of laparoscopic ovarian surgery, particularly in comparison to other treatments, is needed in infertile women with PCOS.

Summary of systematic review evidence
Laparoscopic ovarian surgery versus metformin. Two medium quality RCTs (Level II) (published across three papers) with a moderate risk of bias compared laparoscopic ovarian surgery to metformin and found that there was insufficient evidence to make a recommendation about laparoscopic ovarian surgery compared to metformin for live birth rate per patient, ovulation rate per cycle, pregnancy rate per cycle, pregnancy rate per patient, multiple pregnancies, miscarriage rate per pregnancy, adverse effects and quality of life (QOL; Palomba et al., 2004, 2005; Hamed et al., 2010) largely because the evidence was conflicting. One RCT reported that laparoscopic ovarian surgery was better than metformin for ovulation (OR 2.05; [1.4–2.9] P = 0.001) and pregnancy rate (per cycle: OR 2.19 [1.03–4.63] P = 0.03; per patient: OR 2.47 [1.05–5.81] P = 0.03) (Hamed et al., 2010) and the other study reported that metformin was better than laparoscopic ovarian surgery for live birth rate (metformin: 82.1%, LOS: 64.5%, P < 0.05), pregnancy rate per cycle (metformin: 18.6%, LOS: 13.4%, P < 0.05), and miscarriage rate (metformin: 15.4%, LOS:29.0%, P < 0.05) (Palomba et al., 2004, 2005). Both medium quality single centre studies had a small sample size and moderate risk of bias and therefore need to be interpreted with caution.

Laparoscopic ovarian surgery versus clomiphene citrate. Two high-quality RCTs (Level II) with a low risk of bias compared laparoscopic ovarian surgery to clomiphene citrate (Amer et al., 2009, Abu Hashim, et al. 2011a,b) and found that there was no difference between laparoscopic ovarian surgery and clomiphene citrate for live birth rate per patient and pregnancy rate per patient, ovulation rate per patient and miscarriage rate per pregnancy (Amer et al., 2009, Abu Hashim, et al. 2011a). There was insufficient evidence to support or refute the use of laparoscopic ovarian surgery over clomiphene citrate for multiple pregnancies (Amer et al., 2009, Abu Hashim, et al. 2011a,b).

Laparoscopic ovarian surgery versus clomiphene citrate + metformin. Three low to moderate-quality RCTs with low to moderate risk of bias compared laparoscopic ovarian surgery to clomiphene citrate plus metformin [all three studies reported in Farquhar 2012 systematic review (Farquhar et al., 2012)]. Meta-analyses found that clomiphene citrate plus metformin was better than laparoscopic ovarian surgery for live birth rate, but there was no difference for pregnancy rate per patient, multiple pregnancy rate, or miscarriage rate per pregnancy (Farquhar et al., 2012). There was insufficient evidence to support or refute the use of laparoscopic ovarian surgery over clomiphene citrate plus metformin for ovulation rate per patient, and OHSS (Farquhar et al., 2012).

Laparoscopic ovarian surgery versus AIs. Three RCTs with low risk of bias (Abu Hashim et al., 2010a, Abdellah, 2011; Ibrahim et al., 2017)
compared letrozole to laparoscopic ovarian surgery and found that there was insufficient evidence of a difference between letrozole and laparoscopic ovarian surgery. One of the RCTs in 147 women with clomiphene citrate resistance found that letrozole was better than laparoscopic ovarian surgery for ovulation rate per cycle (Abdellah, 2011), however the evidence is of low certainty. The systematic review by Farquhar et al. (2012) combined these studies in meta-analysis for pregnancy rate per patient, multiple pregnancy rate per pregnancy and miscarriage rate per pregnancy and there was no statistical difference between the two interventions.

**Laparoscopic ovarian surgery versus aromatase inhibitors + metformin.** One low-quality RCT with moderate risk of bias compared laparoscopic ovarian surgery with letrozole plus metformin and found that there was insufficient evidence of a difference between the two interventions for ovulation, pregnancy and miscarriage rate per pregnancy (Abd Elgafor, 2013).

**Laparoscopic ovarian surgery versus gonadotrophins.** One high-quality systematic review of RCTs (Level I) with low risk of bias compared laparoscopic ovarian surgery to gonadotrophins and found that there was no difference between the interventions for live birth rate per patient and pregnancy rate per patient, ovulation rate per patient and miscarriage rate per pregnancy, but laparoscopic ovarian surgery was better than gonadotrophins for multiple pregnancy rate (OR 0.13 [0.03–0.59] I² = 0%, four studies, 303 participants) (Farquhar et al., 2012).

**Summary of narrative review evidence**
Observational data was sourced to evaluate long-term impacts. A 15–25-year follow-up of nearly 150 women after ovarian wedge resection shows that regular menstrual patterns lasting up to 25 years after surgery were restored in 88% of patients with a cumulative pregnancy/live birth rate of 78% (Lunde et al., 2001). This was considered along with the RCT data.

**Justification**
Laparoscopic ovarian surgery is an intervention that can lead to a singleton birth in women with PCOS. There is no convincing evidence of inferiority over other common ovulation induction agents, there is no need for monitoring (because of mono-ovulation) and only a background risk of multiple pregnancy. However, it is important to note that laparoscopic ovarian surgery is an invasive surgical intervention; there is a small risk of reduced ovarian reserve or loss of ovarian function, and adhesion formation should be considered. Issues covered in the CPP should be carefully considered.

**Bariatric surgery**

**Clinical question**
In women with PCOS, what is the effectiveness of lifestyle interventions compared to bariatric surgery for improving fertility and adverse outcomes?

**Clinical need for the question**
Obesity is increasing in prevalence throughout the world, as is morbid obesity (BMI ≥ 40 kg/m²) (Sturm and Hattori, 2013). Women with PCOS have higher rates of weight gain and of obesity, adversely affecting fertility. Weight loss improves outcomes, as previously outlined. In severe obesity, lifestyle interventions have limited efficacy. Substantial efficacy of bariatric surgery on weight loss has been demonstrated in severely obese women. Potential benefits need to be balanced with the delay in infertility treatment and pregnancy for surgery and stabilization of weight, the risks of bariatric surgery and the potential risks of pregnancy after bariatric surgery.

**Controversy persists around efficacy for fertility and pregnancy outcomes, optimal timing, adverse effects and comparative efficacy with other treatments, as well as on adverse effects on subsequent pregnancies.**

**Summary of systematic review evidence**
We did not identify any evidence in women with PCOS to answer the question and therefore the literature has been reviewed narratively.

**Summary of narrative review evidence**
UK clinical guidelines for obesity management in the general population (Scottish Intercollegiate Guidelines Network, 2010) recommend considering bariatric surgery with a BMI ≥35 kg/m² with one or more severe complications expected to improve with weight loss and failure of structured lifestyle intervention (Scottish Intercollegiate Guidelines Network, 2010). Obesity surgery can be considered after non-surgical treatment has failed with a BMI ≥40 kg/m² and obesity surgery can be first line treatment with a BMI ≥50 kg/m² (National Institute for Health and Clinical Excellence, 2006). Other guidelines recommend lower barriers to surgery (Jensen et al., 2014). For type of surgery, vertical sleeve gastrectomy has overtaken the roux-en-Y gastric bypass and gastric band surgery as the most commonly performed bariatric surgery, with lower operative morbidity (Lager et al., 2017). Adjustable gastric banding, once the choice for women planning pregnancy, is now less common given complications and overall lower long-term weight loss (Lager et al., 2017).

High-quality RCTs of bariatric surgery versus medical management in type 2 diabetes mellitus show persistent benefits and superiority of weight loss and bariatric surgery in curing or ameliorating diabetes (Mingrone et al., 2012; Schauer et al., 2017). Yet these studies are absent in PCOS for fertility and pregnancy outcomes, with current PCOS studies poorly designed (Shah and Ginsburg, 2010), and with failure to report key perinatal outcomes to inform risk to benefit ratio. In PCOS, the balance between delaying infertility treatment and pregnancy whilst undertaking bariatric surgery and attaining stable post-operative weight, is also unclear (Mutsaerts et al., 2016), as is the optimal type of bariatric surgery.

Bariatric surgery can cause malabsorption and psychological issues including disordered eating (Månsson et al., 2008) and may adversely affect maternal and neonatal health. Adequate intake and absorption of iron, folate, iodine and other nutrients are of concern. While supplement use is widely recommended following bariatric surgery, especially for pregnant women, there are reports of poor compliance (Nilsen et al., 2006) and challenges tolerating fortified foods such as bread. National registries (surgery, pregnancy, infants) show that obese women who undergo bariatric surgery and conceive, compared to similarly obese controls, had more small for gestational age babies, shorter gestations, and a trend towards increased neonatal mortality (Johansson et al., 2015), with similar findings in retrospective studies.
Benefits have included less gestational diabetes mellitus and large for gestational age babies.

Justification
Bariatric surgery improves weight loss and can improve comorbidities associated with PCOS. However, evidence in relation to fertility and pregnancy outcomes is limited, with some concerns about potential perinatal adverse effects of bariatric surgery. Overall, the indications, role and comparative effectiveness with other fertility therapies, ideal timing, optimal type of surgery, adverse effects and risk to benefit ratio in PCOS are still to be resolved. Given the concerns about the potential perinatal adverse effects of bariatric surgery and the remaining controversies, no recommendation can be made at this time about the use of bariatric surgery to improve fertility and pregnancy outcomes in women with PCOS.

IVF
Clinical question
In women with PCOS, is stimulated IVF/ICSI effective for improving fertility outcomes?

Clinical need for the question
Ovulation induction therapies are first and second line in infertility management in women with PCOS, anovulation and no other fertility factors. Yet resistance to and failure of ovulation induction therapies and inability to overcome other concomitant causes of infertility means that ART therapies, including IVF and ICSI, used in male factor infertility, have a role in PCOS. IVF has risks and limitations, yet also offers the opportunity for pregnancy and live birth. Challenges exist across the diversity of protocols available for IVF and concerns in PCOS including OHSS, high oestradiol levels, accelerated endometrial maturation and optimally the use of ‘freeze all’ interventions. The clinical practice questions here include indications, timing and comparative efficacy with other treatments, yet RCTs in this area are very limited in women with anovulatory PCOS.

Summary of systematic review evidence
We did not identify any evidence in women with PCOS to answer the question and therefore the literature has been reviewed narratively.

Summary of narrative review evidence
There are no RCTs identified by the guideline development team, comparing stimulated IVF ± ICSI therapy with ovulation induction in women diagnosed with PCOS. The role of IVF in PCOS was explored by the WHO guidance group, and the review and recommendations were considered here by the GDG, in making their recommendations (Balen et al., 2016). Factors that influenced considerations here include access, cost and risks. The patient and societal benefits of ovulation induction compared with IVF treatments in anovulatory PCOS women require RCTs and systematic analysis. Outcomes such as time to conception, cost of therapy, QOL, OHSS risk, multiple pregnancy, miscarriage and live birth rates should be investigated.

Justification
The GDG deemed IVF should be considered after failed ovulation induction treatment with high pregnancy rates per cycle, especially in younger women. Given the risks and the high costs that can be prohibitive for many patients, IVF should be considered a third-line medical therapy. It was noted that conception and delivery are highly valued by health professionals and women with PCOS and even when cost and risks are increased, many may elect to undertake IVF. Health professionals must weigh benefits and risk when advising PCOS patients to enable an informed decision.

GnRH protocol
Clinical question
In women with PCOS undergoing IVF/ICSI treatment, is the GnRH antagonist protocol or GnRH agonist long protocol the most effective for improving fertility outcomes?

Clinical need for the question
Women with PCOS are particularly vulnerable to OHSS with IVF ± ICSI treatment, prompting caution and leading to exploration of different protocols, including with GnRH and other options such as IVM (Walls et al., 2015a). One of the proposed methods to reduce the risk of OHSS is to use a GnRH antagonist (as opposed to an agonist) (Al-Inany et al., 2007; Mancini et al., 2011; Lin et al., 2014; American Society for Reproductive Medicine, 2016). There is acknowledged complexity in interpreting outcomes from IVF treatments in PCOS, with variable protocols and endpoint reporting, requiring close evaluation of the literature. One of the proposed methods to reduce the risk of OHSS is to use a GnRH antagonist (as opposed to an agonist) to suppress pituitary LH secretion.

Summary of systematic review evidence
In the eight included studies of low (Hwang et al., 2004; Kurzawa et al., 2008; Tehraninejad et al., 2010), moderate (Bahceci et al., 2005; Lains et al., 2007, 2010; Mokhtar et al., 2015), and high risk of bias (Haydardedeoglu et al., 2012) comparing a GnRH antagonist protocol with a long GnRH agonist protocol, there were statistically significant differences in the amount of gonadotrophin required (five studies in favour of the antagonist protocol) (Hwang et al., 2004; Kurzawa et al., 2008; Lains et al., 2010; Tehraninejad et al., 2010; Haydardedeoglu et al., 2012), in the duration of gonadotrophin use (six studies in favour of the antagonist protocol) (Bahceci et al., 2005; Lains et al., 2007, 2010; Kurzawa et al., 2008; Tehraninejad et al., 2010; Haydardedeoglu et al., 2012), in OHSS rates (two studies in favour of the antagonist protocol) (Lains et al., 2007; Tehraninejad et al., 2010). No statistically significant differences were found between groups for clinical pregnancy rates, miscarriage rates, number of oocytes collected, cancellation rates, and multiple pregnancy rates.

A systematic review and meta-analysis comparing the GnRH antagonist protocol versus GnRH agonist long protocol in women with PCOS undergoing an IVF ± ICSI cycle (Pundir et al., 2012) was also identified by the search, however it included studies that did not meet the selection criteria for this question. The GDG considered this meta-analyses as clinically relevant. The meta-analysis demonstrated a statistically significantly reduction in the total dose of gonadotrophins, duration of gonadotrophin stimulation and rate of moderate to severe OHSS with the GnRH antagonist protocol, with no statistically significant difference in clinical pregnancy, miscarriage or number of eggs collected.
Justification
The duration of stimulation with a GnRH antagonist approach is around 1 day shorter than the standard ‘long-down regulation’ approach with a GnRH agonist. The rate of OHSS appears less with a GnRH antagonist approach in comparison to the standard ‘long-down regulation’ approach with a GnRH agonist. The effect size is difficult to quantify, as all most of these studies used a high dose hCG trigger in both arms, whereas this may not reflect clinical practice. There does not appear to be an increase in undesirable side-effects with an antagonist down-regulation approach. The choice to trigger final oocyte maturation with GnRH agonist instead of hCG is important to prevent OHSS.

Trigger type
Clinical question
In women with PCOS undergoing GnRH antagonist IVF/ICSI treatment, is the use of hCG trigger or GnRH agonist trigger the most effective for improving fertility outcomes?
Clinical need for the question
One of the prominent causes of OHSS is the occurrence in women with PCOS undergoing ovarian hyperstimulation for IVF, particularly where hCG is used to trigger ovulation. Early in 1990, an alternative to exogenous hCG triggering emerged with GnRH-agonist use, providing an additional ovulatory option for IVF. A single bolus of GnRH-agonist administration during late follicular development in women with PCOS treated with gonadotrophins results in a surge of endogenous FSH and LH for final oocyte maturation and fertilization. OHSS appears reduced yet lower pregnancy rates with GnRH-agonist triggers are observed and may vary when transferring fresh versus frozen-thawed embryos in cycles from the same cohort, suggesting that the pregnancy rate is dependent of endometrial quality. An alternative option therefore in women with PCOS at high risk of OHSS is to freeze oocytes or embryos after GnRH agonist triggering and transfer the embryos in subsequent cycles. The choice to trigger final oocyte maturation with GnRH-agonist, instead of hCG, and to transfer frozen embryos requires clarification.

Summary of systematic review evidence
We did not identify any evidence in women with PCOS to answer the question and therefore the literature has been reviewed narratively.

Summary of narrative review evidence
This question was addressed in a Cochrane review in 2014 (Youssef et al., 2014). In 17 RCTs (n = 1847), in fresh autologous cycles, GnRH-agonists were associated with a lower live birth rate than hCG (OR 0.47, 95% CI 0.31–0.70; five RCTs, 532 women, I² = 56%, moderate-quality evidence), yet there was also a lower incidence of mild, moderate or severe OHSS than with hCG (OR 0.15, 95% CI 0.05–0.47; 8 RCTs, 989 women, I² = 42%, moderate-quality evidence). In fresh autologous cycles, GnRH-agonists were associated with a lower ongoing pregnancy rate than hCG (OR 0.70, 95% CI 0.54–0.91; 11 studies, 1198 women, I² = 59%, low-quality evidence) and a higher early miscarriage rate (OR 1.74, 95% CI 1.10–2.75; 11 RCTs, 1198 women, I² = 1%, moderate-quality evidence). However, the effect was dependent on the type of luteal phase support provided. Multiple pregnancy rates were similar. The authors concluded that final oocyte maturation triggering with GnRH-agonist instead of hCG in fresh autologous GnRH-antagonist IVF ± ICSI cycles prevents OHSS to the detriment of the live birth rate. In donor-recipient cycles, use of GnRH agonists instead of hCG resulted in a lower incidence of OHSS, with no evidence of a difference in live birth rate. GnRH agonist as an oocyte maturation trigger could be useful for women who choose to avoid fresh transfers, where donated oocytes are used or in women who wish to freeze their eggs for later use.

Justification
The choice to trigger final oocyte maturation with GnRH-agonist instead of hCG is important in prevention of OHSS as hCG alone induces oocyte maturation but is associated with OHSS. GnRH-agonist triggers are associated with lower pregnancy rates, primarily in fresh embryo transfers, and data on cumulative pregnancy rates after the use of all embryos frozen and replaced in thawed cycles needs specific focus in the future.
Choice of FSH

Clinical question
In women with PCOS undergoing (controlled) ovarian (hyper) stimulation for IVF/ICSI, does the choice of FSH effect fertility outcomes?

Clinical need for the question
FSH can be purified from human urine (uFSH) or synthesized using recombinant DNA techniques (rFSH). Urinary preparations have impurities with LH activity known to stimulate androgen production in theca cells and completing maturation of follicles. However, it is known that less than 1% of follicular LH receptors needs to be occupied in order to elicit maximal steroidogenesis and it is therefore possible that enough endogenous LH is present during controlled ovarian stimulation to promote androgen synthesis and oocyte maturation without the need for extra LH activity in FSH preparations. The perceived clinical benefits of rFSH versus uFSH are the subject of ongoing debate and both types of preparations remain commonly used.

Summary of systematic review evidence
One small study (80 participants) with moderate risk of bias compared rFSH with hMG and found that rFSH was better for the duration of ovarian stimulation required and the number of oocytes retrieved; whereas hMG was better for the maximum serum estradiol level (Figen Turkcapar et al., 2013). No statistically significant differences were found between groups for the total dose of gonadotrophin used, OHSS rate, clinical pregnancy rate per cycle and take home baby rate per cycle.

Summary of narrative review evidence
Given the limited evidence in PCOS, additional information was sought from rFSH and uFSH use in the general population. In a Cochrane systematic review and meta-analysis, 42 trials with a total of 9606 couples compared rFSH against three different uFSH preparations (van Wely et al., 2011). rFSH, irrespective of the down-regulation protocol, did not result in a statistically significant different live birth rate or OHSS rate, concluding that clinical choice of gonadotrophin should depend on availability, convenience and costs, and that further research on these comparisons is unlikely to identify substantive differences in effectiveness or safety.

Justification
Only one small study in PCOS has been identified investigating uFSH versus rFSH in PCOS during ovarian stimulation for IVF/ICSI (Figen Turkcapar et al., 2013). This study shows similar results to a systematic review and meta-analysis in the general IVF population, where extensive research has concluded no significant difference in birth rate or OHSS was detected and no further research in the general population was recommended. Hence clinical choice of gonadotrophin should depend on availability, convenience and costs.

Exogenous LH

Clinical question
In women with PCOS undergoing (controlled) ovarian (hyper) stimulation for IVF/ICSI, is exogenous LH treatment during IVF±ICSI effective for improving fertility outcome?

Clinical need for the question
Options have been explored to reduce OHSS risk in IVF/ICSI in PCOS. The low-dose step-up protocol with exogenous FSH in securing single (fewer) dominant follicle selection is an alternative method to avoid multifollicular development. During late follicular development, LH is essential to achieve adequate ovarian steroidogenesis and develop the subsequent capacity of the follicle to ovulate and luteinize. Increased LH secretion or elevated LH/FSH ratio in PCOS may influence fertility, with inhibition of oocyte maturation, deleterious effects on granulosa cell steroidogenesis and endometrial receptivity and with potential increased early pregnancy loss (Jacobs and Homburg, 1990; Tarlatzis et al., 1995; Willis et al., 1998). The lack of clarity around the role of exogenous LH in the setting of IVF/ICSI prompted this clinical question.

Summary of systematic review evidence
We did not identify any evidence in women with PCOS to answer the question and therefore the literature has been reviewed narratively.

Summary of narrative review evidence
Obesity adversely impacts on ovulation and on responses to ovulation induction in PCOS (Kiddy et al., 1990). In PCOS, granulosa cells respond to LH at a relatively earlier follicular stage and are significantly more responsive than for ovulatory women with PCOS or women without PCOS (Willis et al., 1998). Granulosa cell differentiation may be prematurely advanced. Controlled ovarian stimulation for multiple follicular development in ART can be performed in a variety of ways to increase efficacy and reduce risks. Systematic reviews and meta-analysis have demonstrated that there is no significant difference between different ovarian stimulation protocols (hMG, purified FSH, rFSH) regarding the fertility outcomes. Therefore, clinical gonadotrophin choice depends on availability, convenience, and cost. In standard IVF/ICSI protocols, the types of controlled ovarian stimulation (FSH alone or addition of LH as a supplement) have little impact on the fertility outcomes (van Wely et al., 2011; Schwarze et al., 2016). Endogenous LH levels may fall too low in older women (>35 years) during ovarian stimulation, especially with GnRH-antagonist use, and LH supplementation has been proposed. However, a multi-centre RCT of exogenous LH during the follicular phase showed no fertility benefit outcomes in women over 35 years of age (Kong et al., 2013). No current study investigates efficacy of exogenous LH supplement for fertility outcomes in PCOS during IVF/ICSI. Careful monitoring of follicular development during ovarian stimulation is critical.

Justification
There is no anticipated effect or benefit to add exogenous LH supplement in women with PCOS undergoing ovarian stimulation for IVF±ICSI. There is insufficient evidence to determine the benefits of using or not using exogenous LH.

Adjunct metformin

Clinical question
In women with PCOS undergoing (controlled) ovarian (hyper) stimulation for IVF±ICSI, is adjunct metformin effective for improving fertility outcomes?
Summary of systematic review evidence
Six RCTs of low (Kjotrod et al., 2004; Tang et al., 2006; Palomba et al., 2011), moderate (Kjotrod et al., 2011) and high risk of bias (Fedorcsak et al., 2003; Onalan et al., 2005) found that IVF with adjuvant metformin was better for OHSS, clinical pregnancy rate, cancellation rate and live birth rate. No statistically significant differences were found between groups for the amount of gonadotrophins used, the duration of ovarian stimulation, miscarriage rates, number of oocytes collected, and multiple pregnancy rates.

Summary of narrative review evidence
A Cochrane review (Tso et al., 2014) was identified by the search, however it included studies that did not meet the selection criteria for this question. The GDG considered the meta-analyses in the Cochrane review as clinically relevant and noted that there was no evidence of a difference with adjunct metformin for live birth rate, miscarriage rate, number of oocytes collected, days of ovarian stimulation or cycle cancellation rate; and clinical pregnancy rate was increased with adjuvant metformin whilst OHSS was reduced. Mild, generally self-limiting side-effects, were noted with adjunct metformin, as outlined in Chapter 4.

Justification
Women and health professionals would generally value an increased clinical pregnancy rate (with no evidence of a difference in miscarriage rate) and reduced OHSS (with its associated morbidity and rarely mortality). Gastrointestinal side-effects were recognized, but noted as mild and self-limiting, and may be minimized with a lower metformin starting dose and extended release preparations. Metformin was noted to be low cost and readily available, and while off label use was generally allowed, an explanation is required for use.

IVM
Clinical question
In women with PCOS, is IVM effective for improving fertility outcomes?

Clinical need for the question
IVF±ICSI treatment in women with PCOS is usually recommended either third-line (after failed ovulation induction) or in those with other infertility factors such as tubal damage, severe endometriosis or male factors (Baskind and Balen, 2016). IVF±ICSI treatment in PCOS poses challenges, including OHSS (Costello et al., 2006). Metformin has been studied to restore ovulation and enhance pregnancy rates in PCOS (Huang et al., 2015) through a range of mechanisms (Kjotrod et al., 2004, 2011; Lin and Coutifaris, 2007). These mechanisms provide a physiological rationale for management of insulin resistance in IVF in PCOS. It has also been suggested that metformin may reduce serum estradiol levels during ovarian stimulation and it has also been hypothesized that metformin may reduce the production of vascular endothelial growth factor, both of which are important factors involved in the pathophysiology of OHSS (Legro, 2016). Therefore, it was deemed important to explore the effectiveness and safety of metformin as a co-treatment in achieving pregnancy or live birth and reducing OHSS in IVF in PCOS.

Summary of narrative review evidence
With an absence of relevant RCTs (Sauerbrun-Cutler et al., 2015), retrospective studies suggest IVM is similarly successful for live birth with frozen embryos generated with IVM as embryo transfers generated by standard IVF treatment (Walls et al., 2015a). However, pregnancy rates are reduced and miscarriage rates are higher if a fresh embryo transfer is performed with IVM (Walls et al., 2015a). Embryo development appears slower with a greater degree of embryo arrest in IVM (Walls et al., 2015b; Roesner et al., 2017a).

Justification
The GDG deemed that key elements to consider with IVM included a clear definition of the term IVM, use in clinical units with sufficient expertise and the advantages of a reduced risk of OHSS. The group considered the lack of evidence as important. It was considered that IVM could be offered to achieve pregnancy and live birth rates that may approach those of standard IVF ± ICSI treatment, where frozen embryos are used. Given the lack of evidence, the group voted for a conditional consensus recommendation that neither favoured this option or other options (IVF), with strong research recommendations.

Discussion
The recommendations in the international evidence-based guidelines were formulated after engagement with professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. AGREE II-compliant processes were followed, with extensive evidence synthesis. The GRADE framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength.

The evidence and recommendations for ovulation induction in this guideline are applicable to women with PCOS who have anovulatory infertility and no other infertility factors. The discussion will be limited to what recommendations are considered new as compared to previous guidelines.

Letrozole should now be considered the first line pharmacological treatment for ovulation induction (EBRs, strong recommendation, low
Evidence summary and recommendations on PCOS management

PCOS guideline translation program
A comprehensive, international translation and dissemination program is currently underway to disseminate, translate and amplify the impact of the International Evidence-based Guideline on the Assessment and Management of Polycystic Ovary Syndrome. The program is inclusive of a range of practice support tools including a GP tool, care plan, a set of five algorithms (available at: https://www.monash.edu/medicine/sphpm/mchri/pcos/resources/practice-tools-for-health-practitioners), and resources to increase the PCOS related health literacy of consumers (Fig. 2 PCOS consumer information graphic—PCOS fertility and pregnancy) (available at: https://www.monash.edu/medicine/sphpm/mchri/pcos/resources/responses-for-women-with-pcos). In addition, the first evidence-based PCOS App (AskPCOS) (Fig. 3 Screenshots of the PCOS App—AskPCOS) has been developed and now available for purchase at iTunes. AskPCOS has a range of innovative features including a self-diagnostic quiz, a comprehensive repository of information on PCOS, a range of info-graphics, videos by experts, and a question prompt list to build health practitioner interaction skills.

The comprehensive evidence reviews, profiles and GRADE frameworks supporting each recommendation, can be found in the supplementary Technical report (2018) Available at: https://www.monash.edu/__data/assets/pdf_file/0020/1412282/PCOS-Guideline_Technical-report.pdf

Acknowledgements
We gratefully acknowledge the collaborating societies and consumer groups available at: https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline.

Authors’ roles
Helena Teede, Robert Norman, Michael Costello and Marie Misso were members of the project board, and coordinated Guideline Development Group (GDG) activities from prioritizing clinical questions, providing clinical input into evidence synthesis, chairing the GDG process and GRADE framework application, finalizing recommendations, responding to feedback and endorsing the guideline.

Helena Teede was the guideline development and translation lead and engaged with all GDG meetings, overseeing the process.

Michael Costello chaired the GDG on the assessment and management of infertile women with PCOS. Marie Misso led the guideline development and evidence synthesis processes.

Robert Norman was the PCOS Centre for Research Excellence co-director, the deputy chair of the International advisory board and the deputy chair of the GDG.

All other authors, were actively engaged as GDG members, consumer, translation, or international advisory board members or members of the evidence synthesis and translation team, contributed to the manuscript, prioritizing clinical questions, discussing recommendations until voting and consensus, responses to external peer review and approval of the final recommendations for the GDG.

Funding
The Australian National Health and Medical Research Council (NHMRC) funded guideline development through the NHMRC Centre for Research Excellence in Polycystic Ovary Syndrome (APP1078444), administered through Monash University and University of Adelaide, Australia. Guideline partners, ESHRE and the American Society for Reproductive Medicine (ASRM) provided additional funding and assisted in guideline development activities.

QOE although evidence was of moderate quality for the outcomes of ovulation, pregnancy and live-birth rates) although one could use clomiphene citrate alone (EBRs, conditional recommendation, very low QOE) or metformin alone (EBRs, conditional recommendation, moderate QOE). If using metformin alone for ovulation induction, then one should inform the woman that there are more effective ovulation induction agents.

Gonadotrophins could also be considered as first line ovulation induction treatment, in the presence of ultrasound monitoring, and following counselling on cost and potential risk of multiple pregnancy (EBR, conditional recommendation, low QOE). Gonadotrophins should be used in preference to clomiphene citrate combined with metformin therapy for ovulation induction in clomiphene citrate-resistant women with PCOS to improve live birth rates (EBRs, strong recommendation, moderate QOE). Gonadotrophins with the addition of metformin could be used rather than gonadotrophins alone to improve live birth rates in clomiphene citrate-resistant PCOS women (EBRs, conditional recommendation, moderate QOE).

Both pharmacological anti-obesity agents and bariatric surgery should be considered experimental ovulation induction therapies for the purpose of improving fertility and having a baby, with risk to benefit ratios currently too uncertain to advocate these as fertility therapies (CCR, conditional recommendation against the options, QOE not applicable).

In the absence of an absolute indication for IVF ± ICSI, women with PCOS and anovulatory infertility could be offered IVF as third-line therapy where first or second line ovulation induction therapies have failed (CCR, conditional recommendation, QOE not applicable). In terms of the controlled ovarian hyperstimulation for IVF ± ICSI, a GnRH antagonist protocol is preferred to reduce the duration of stimulation, total gonadotrophin dose and incidence of OHSS (EBR, conditional recommendation, low QOE), uFSH or rFSH can be used due to insufficient evidence to recommend specific FSH preparations (CCR, conditional recommendation, QOE not applicable), and exogenous recombinant LH treatment should not be routinely used in combination with FSH therapy (CCR, conditional recommendation, QOE not applicable). Adjunct metformin therapy could be used before and/or during FSH ovarian stimulation for IVF ± ICSI therapy with a GnRH-agonist protocol, to improve the clinical pregnancy rate and reduce the risk of OHSS (EBR, conditional recommendation, low QOE).

In units with sufficient expertise, IVM could be offered to achieve pregnancy and live birth rates approaching those of standard IVF ± ICSI treatment without the risk of OHSS for women with PCOS, where an embryo is generated, then vitrified and thawed and transferred in a subsequent cycle (CCR, conditional recommendation for either the IVM or standard IVF ± ICSI treatment, QOE not applicable).
Conflict of interest

Disclosures of conflicts of interest were declared at the outset and updated throughout the guideline development process, aligned with NHMRC guideline processes. Dr Costello has declared shares in Virtus Health and past sponsorship from Merck Serono for conference presentations. Prof. Norman has declared a minor shareholder interest in the IVF unit Fertility SA, travel support from Merck and grants from Ferring. Prof. Norman also has scientific advisory board duties for Ferring. The remaining authors have no conflicts of interest to declare. The guideline was peer-reviewed by special interest groups across our partner and collaborating societies and consumer organizations, was independently assessed against AGREE II criteria, and underwent methodological review. This guideline was approved by all members of the GDG and was submitted for final approval by the NHMRC.

References

Abd Elgafor I. Efficacy of combined metformin-letrozole in comparison with bilateral ovarian drilling in clomiphene-resistant infertile women with polycystic ovarian syndrome. Arch Gynecol Obstet 2013;1:119–123.

Abdellah MS. Reproductive outcome after letrozole versus laparoscopic ovarian drilling for clomiphene-resistant polycystic ovary syndrome. Int J Gynaecol Obstet 2013;1:218–221.

Abu Hashim H, Bazeed M, Abd Elal I. Minimal stimulation or clomiphene citrate as first-line therapy in women with polycystic ovary syndrome: a randomized controlled trial. Gynecol Endocrinol 2011;2:87–90.

Abu Hashim H, Foda O, Ghayaty E. Combined metformin-clomiphene in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Acta Obstet Gynecol Scand 2015;9:921–930.

Abu Hashim H, Foda O, Ghayaty E, Elawa A. Laparoscopic ovarian diathermy after clomiphene failure in polycystic ovary syndrome: is it worthwhile? A randomized controlled trial. Arch Gynecol Obstet 2011a;5:1303–1309.

Abu Hashim H, Mashaly AM, Badawy A. Letrozole versus laparoscopic ovarian diathermy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. Arch Gynecol Obstet 2010a;5:567–571.

Abu Hashim H, Shokeir T, Badawy A. Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 2010b;4:1405–1409.

Abu Hashim H, Wafa A, El Rakhawy M. Combined metformin and clomiphene citrate versus highly purified FSH for ovulation induction in clomiphene-resistant PCOS women: a randomised controlled trial. Gynecol Endocrinol 2011b;3:190–196.

Adase E. Clomiphene citrate: mechanism(s) and site(s) of action—a hypothesis revisited. Fertil Steril 1984;42:331–344.

Al Subhi T, Al Jashmi RN, Al Khadun M, Gowri V. Prevalence of tubal obstruction in the hysterosalpingogram of women with primary and secondary infertility. J Reprod Infert 2013;4:214–216.

Al-Inany HG, Abou-Setta AM, Aboughlah M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online 2007;5:640–649.

Amer S, Li T, Metwally M, Emrah M, Ledger W. Randomized controlled trial comparing laparoscopic ovarian diathermy with clomiphene citrate as a first-line method of ovulation induction in women with polycystic ovary syndrome. Hum Reprod 2009;1:219–225.

Atay V, Cam C, Muhcu M, Cam M, Karateke A. Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Int Med Res 2006;1:73–76.

Badawy A, Abdel Aal I, Abulatta M, Caballero AE. Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial. Fertil Steril 2009;3:849–852.

Bahceci M, Ulug U, Ben-Shlomo I, Erden HF, Akman MA. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. J Reprod Med 2005;2:84–90.

Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, Stener-Victorin E, Fauser BC, Norman RJ, Teede H. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update 2016;6:687–708.

Banerjee Ray P, Ray A, Chakraborti PS. Comparison of efficacy of letrozole and clomiphene citrate in ovulation induction in Indian women with polycystic ovarian syndrome. Arch Gynecol Obstet 2012;3:873–877.

Baskind NE, Balen AH. Hypothalamic-pituitary, ovarian and adrenal contributions to polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2016;37:80–97.

Bayar U, Kiran S, Coskun A, Gezer S. Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial. Fertil Steril 2006;5:1447–1451.

Begum MR, Akhter S, Ehsan M, Begum MS, Khan F. Pretreatment and co-administration of oral anti-diabetic agent with clomiphene citrate or rFSH for ovulation induction in clomiphene-citrate-resistant polycystic ovary syndrome. J Obstet Gynaecol Res 2013;5:966–973.

Begum MR, Ferdous J, Begum A, Quadir E, Begum MR, Ferdous J, Begum A, Quadir E. Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. Fertil Steril 2009;3:853–857.

Biljan M, Hemmings R, Brassard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil Steril 2005;5:231–231. Abstract 1033.

Bordewijk EM, Nahuis M, Costello MF, Van der Veen F, Tso LO, Mol BWJ, van Wely M. Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2017. DOI:10.1002/14651858.CD009090.pub2.Art No.: CD009090.

Broseea K, Opmeer BC, Van Geloven N, Coppus SF, Collins JA, Den Hartog JE, Van der Linden P, Marianowski P, Ng EH, Van der Steeg JW, et al. Are patient characteristics associated with the accuracy of hysterosalpingography in diagnosing tubal pathology? An individual patient data meta-analysis. Hum Reprod Update 2011;3:293–300.

Brown J, Farquhar C. Clomiphene and other anti-oestrogens for ovulation induction in polycystic ovarian syndrome. Cochrane Database Syst Rev 2016;3:CD002249.

Casper R. Letrozole: Ovulation or superovulation? Fertil Steril 2003;6:1335–1337.

Chian R-C. In-vivo maturation of immature oocytes for infertile women with PCOS. Reprod BioMed Online 2004;5:547.

Clark A, Ledger W, Galletty C, Tomlinson L, Blaney F, Wang X, Norman R. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10:2705–2712.

Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Brown J, Farquhar C. Clomiphene and other antioestrogens for ovulation induction in clomiphene-resistant polycystic ovarian syndrome. Cochrane Database Syst Rev 2016;12:CD002249.

Costello MF, Chapman M, Conway U. A systematic review and meta-analysis of randomized controlled trials on metformin co-administration
during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. *Hum Reprod* 2006;6:1387–1399.

Costello M, Eden J. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. *Fertil Steril* 2003;79:1–13.

Costello MF, Misso ML, Wong J, Hart R, Rombauts L, Melder A, Norman RJ, Teede HJ. The treatment of infertility in polycystic ovary syndrome: a brief update. *Aust N Z Obstet Gynaecol* 2012;4:400–403.

Davies MJ, Moore VM, Willson KJ, Robinson RD, Casson P, Christman GM, Ager J, Huang H, Hansen KR et al. Letrozole, gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. *Hum Reprod* 1999;4:1095–1099.

Haydardeodeoglu B, Kilidag EB, Parlagkumus AH, Zeyneloglu HB. IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial. *Arch Gynecol Obstet* 2012;3:763–769.

Healey S, Tan S, Tulandi T, Biljan M. Effects of letrozole on superovulation with gonadotrophin in women undergoing intrauterine insemination. *Fertil Steril* 2003;80:1325–1329.

Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzik D. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. *Clin Endocrinol Metab* 2008;11:4299–4306.

Holzer H, Casper R, Tulandi T. A new era in ovulation induction. *Fertil Steril* 2006;85:277–284.

Homburg R. Management of infertility and prevention of ovarian hyperstimulation in women with polycystic ovary syndrome. *Best Pract Res Clin Obstet Gynaecol* 2004;5:773–788.

Homburg R, Hendriks ML, Kong TE, Anderson RA, Balen AH, Brincat M, Child T, Davies M, D’Hooghe T, Martinez A et al. Clomiphene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. *Hum Reprod* 2012;2:468–473.

Huang X, Wang P, Tai R, Lv F, Li Y, Zhang X. A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures. *Int J Gynaecol Obstet* 2015;13:111–116.

Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, Wu GJ, Huang SC, Chen CY, Chen PH et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pretreatment for patients with polycystic ovary syndrome: a prospective randomized study. *Hum Reprod* 2004;9:1993–2000.

Ibrahim MH, Tawfic M, Hassan MM, Sedky OH. Letrozole versus laparoscopic ovarian drilling in infertile women with PCOS resistant to clomiphene citrate. *Middle East Fertil Soc J* 2017;4:251–254.

Imani B, Eijkmans MJ, Faessen GH, Bouchard P, Giudice LC, Fauser BC. Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. *Fertil Steril* 2002;1:83–90.

Imani B, Eijkmans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. *Hum Reprod* 2002;7:1477–1485.

International evidence-based guidelines for the assessment and management of polycystic ovary syndrome (2018). Melbourne, Monash University.
randomized controlled trial: effect on hormonal levels and follicular development. Hum Reprod 2007; 22:1540–1546.

Lainas TG, Sfourentou IA, Zorzovilis IZ, Petasas GK, Lainas GT, Alexopoulos E, Kolibianakis EM. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Hum Reprod 2010; 25:683–689.

Legro RS. Ovulation induction in polycystic ovary syndrome: current options. Best Pract Res Clin Obstet Gynaecol 2016; 31:152–159.

Legro SR, Arslanian AS, Ehrmann DA, Hoeger MK, Murad HM, Pasquali KR, Welt KC. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2013; 98:4565–4592.

Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356:551–566.

Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014a; 370:119–129.

Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014b; 370:119–129. [Erratum appears in N Engl J Med. 2014 Oct 9;317(15):1465].

Legro RS, Dodson WC, Kris-Etherton PM, Kunsman AR, Stetter CM, Williams NI, Gnatuk CL, Estes SJ, Fleming J, Allison KC et al. Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome. J Clin Endocrinol Metab 2015; 101:4048–4058.

Lin K, Coutifaris C. In vitro fertilization in the polycystic ovary syndrome patient: an update. Clin Obstet Gynecol 2007; 1:268–276.

Lin H, Li Y, Li L, Wang W, Yang D, Zhang Q. Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs. PLoS One 2014; 9:e91796.

Lopez E, Gunby J, Daya S, Parrilla J, Abad L, Balasch J. Ovulation induction in women with polycystic ovary syndrome: randomized trial of clomiphene citrate versus low-dose recombinant FSH as first line therapy. Reprod Biomed Online 2004; 9:382–390.

Lunde O, Djoseland O, Grottum P. Polycystic ovarian syndrome: a follow-up study on fertility and menstrual pattern in 149 patients 15–25 years after ovarian wedge resection. Hum Reprod 2001; 17:4697–4698.

Lunenfeld B, Insler V. Classification of amenorrhoeic states and their treatment by ovulation induction. Clin Endocrinol (Oxf) 1974; 2:223–237.

Luttjeboer F, Verhoeven KL, Hesselt H, van Een F, van Mol B, Coppus S. The value of medical history taking as risk indicator for tuboperitoneal pathology: a systematic review. BJOG 2009; 116:612–625.

Maged AM, Elsavah H, Abdelhafeza A, Bakry A, Mostafa WA. The adjuvant effect of metformin and N-acetylcycteine to clomiphene citrate in induction of ovulation in patients with Polycystic Ovary Syndrome. Gynecol Endocrinol 2015; 31:635–638.

Mancini F, Tur R, Martinez F, Coroleu B, Rodriguez I, Barri PN. Gonadotrophin-releasing hormone-antagonists vs long agonist in in-vitro fertilization patients with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol 2011; 3:150–155.

Mingrone G, Panunzi S, De Gaetano A, Guidone I, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366:1577–1585.

Misso ML, Wong JL, Teede HJ, Hart R, Rombauts L, Melder AM, Norman RJ, Costello MF. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. Hum Reprod Update 2012; 3:301–312.
Evidence summary and recommendations on PCOS management

Mitwally M, Casper R. Use of an aromatase inhibitor for induction of ovulation in women with an inadequate response to clomiphene citrate. Fertil Steril 2001; 75:305–309.

Mohktar S, Sadeghi MR, Akhondi MM, Zafaroudost S, Badenush B, Fatemi F, Nazari F, Kamali K, Mohammadzade A. ART outcomes in GnRH antagonist protocol (Flexible) and long GnRH agonist protocol during early follicular phase in patients with polycystic ovary syndrome: a randomized clinical trial. J Reprod Infertil 2015; 3:148–154.

Morley LC, Tang T, Yasmin E, Norman RJ, Baile AH. Insulin-sensitizing drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhea and subfertility. Cochrane Database Syst Rev 2017; 11:CD003053.

Mukherjee S, Sharma S, Chakravarty BN. Comparative evaluation of pregnancy outcomes in gonadotrophin-clomiphene combination vs clomiphene alone in polycystic ovarian syndrome and unexplained infertility—A prospective clinical trial. J Hum Reprod Sci 2010; 2:80–84.

Mutsaerts MA, van Oers AM, Groen H, Burggraaff JM, Kuchenbecker WK, Perquin DA, Koks CA, van Golde R, Kaaijk EM, Schierbeek JM et al. Randomized trial of a lifestyle program in obese infertile women. N Engl J Med 2016; 374:1942–1953.

Månsson M, Holte J, Landin-Wilhelmsen K, Dahlgren E, Johansson A, Landén M. Women with polycystic ovary syndrome are often depressed or anxious—a case control study. Psychoneuroendocrinology 2008; 33:1132–1138.

National Health and Medical Research Council. NHMRC levels of evidence and grades for recommendations for developers of guidelines. Australia: National Health and Medical Research Council, 2009.

National Institute for Health and Clinical Excellence. NICE clinical guideline 43: Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. London, UK: National Institute for Health and Clinical Excellence, 2006.

Nakiz H, Kumtepe Y. Comparison of efficacy of letrozole and clomiphene citrate in ovulation induction for women with polycystic ovarian syndrome. HealthMED 2012; 3:879–883.

Nilsen R, Vollset S, Gjessing H, Magnus P, Meltzer H, Haugen M, Ueland P. Patterns and predictors of folic acid supplement use among pregnant women: the Norwegian Mother and Child Cohort Study. Am J Clin Nutr 2006; 84:1134–1141.

Nugent D, Vandekerckhove P, Hughes E, Arnott M, Lilford R. Gonadotrophin therapy for ovulation induction in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2000; 4:CD000410.

Onalan G, Pabuccu R, Goktolga U, Ceyhan T, Bagis T, Cinick M. Metformin treatment in women with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertil Steril 2005; 83:798–801.

Palomba S, Falbo A, Carrillo L, Villani MT, Orino F, Russo T, Di Cello A, Cappiello F, Capasso S, Tolino A et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertil Steril 2011; 96:1384–1390.e1384.

Palomba S, Falbo A, Zullo F. Management strategies for ovulation induction in subfertility associated with polycystic ovary syndrome. J Hum Reprod Sci 2011; 4:215–220.

Palomba S, Orino F, Nardo L, Falbo A, Russo T, Corea D, Doldo P, Lombardi G, Tolino A, Colao A et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:4801–4809.

Palomba S, Pasquali R, Orto F, Nestler JE. Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. Clin Endocrinol (Oxf) 2009; 2:311–321.

American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril 2016; 105:1634–1647.

Pritts E. Letrozole for ovulation induction and controlled ovarian hyperstimulation. Curr Opin Obstet Gynecol 2010; 22:289–294.

Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod Biomed Online 2012; 24:6–22.

Reavey J, Vincent K, Child T, Granne IE. Human chorionic gonadotrophin priming for fertility treatment with in vitro maturation. Cochrane Database Syst Rev 2016; 11:CD008720.

Roesner S, Dietrich JE, Weigert J, Montag M, Toth B, Strowitzki T. Time-lapse imaging reveals differences in growth dynamics of embryos after in vitro maturation compared with conventional stimulation. Fertil Steril 2017a; 108:606–612.e603.

Roesner S, von Wolff M, Elsasser M, Roesner K, Reuner G, Pietz J, Bruckner T, Strowitzki T. Two-year development of children conceived by IVF: a prospective controlled single-blinded study. Hum Reprod 2017b; 32:1341–1350.

Rosing M, Daing J, Weiss N. Ovarian tumours in a cohort of infertile women. N Engl J Med 1994; 331:771–776.

Roy K, Baruah J, Singla S, Sharma J, Singh N, Jain S, Goyal M. A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. J Hum Reprod Sci 2012; 5:20–25.

Sauerbrunn-Cutler MT, Vega M, Keltz M, McGovern PG. In vitro maturation and its role in clinical assisted reproductive technology. Obstet Gynecol Surv 2015; 10:45–57.

Schankath AC, Fasching N, Urech-Ruh C, Hohl MK, Kubik-Huch RA. Hysterosalpingography in the workup of female infertility: indications, technique and diagnostic findings. Insights Imaging 2012; 3:475–483.

Schauer PR, Bhatt DL, Kashyap SR. Bariatric surgery or intensive medical therapy for diabetes after 5 years. N Engl J Med 2017; 376:1997–2000.

Schwarz JE, Crosby JA, Zegers-Hochschild F. Addition of neither recombinant nor urinary luteinizing hormone was associated with an improvement in the outcome of autologous in vitro fertilization/intracytoplasmatic sperm injection cycles under regular clinical settings: a multicenter observational analysis. Fertil Steril 2016; 105:1714–1717.e1711.

Scottish Intercollegiate Guidelines Network. Management of obesity: A national clinical guideline. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network, 2010.

Selim MF, Borg TF. Letrozole and clomiphene citrate effect on endometrial and subendometrial vascularity in treating infertility in women with polycystic ovary syndrome. J Gynecol Surg 2012; 26:405–410.

Shah D, Ginsburg E. Bariatric surgery and fertility. Curr Opin Obstet Gynecol 2011; 23:248–254.

Sharma S, Ghosh S, Singh S, Chakravarty A, Ganesh A, Rajani S, Chakravarty BN. Congenital malformations among babies born following letrozole or clomiphene for infertility treatment. PLoS One 2014; 10:e108219.

Sheikh-El-Arab Elsdeek M, Elmaghraby HAH. Predictors and characteristics of letrozole induced ovulation in comparison with clomiphene induced ovulation in anovulatory PCOS women. Middle East Fertil Soc J 2011; 2:125–130.
Shelly W, Draper M, Krishvan V, Wong M, Jaffe R. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 2008;63:163–181.

Stein I. Duration of infertility following ovarian wedge resection. West J Surg 1964;72:237–242.

Sturm R, Hatton A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond) 2013;36:889–891.

Tang T, Glanville J, Orsi N, Barth JH, Balen AH. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 2006;6:1416–1425.

Tarlatzis BC, Grimbizis G, Pournaropoulos F, Bontis J, Lagos S, Spanos E, Mantalenakis S. The prognostic value of basal luteinizing hormone:follicle-stimulating hormone ratio in the treatment of patients with polycystic ovarian syndrome by assisted reproduction techniques. Hum Reprod 1995;10:2545–2549.

Tatsumi T, Jwa SC, Kuwahara A, Irahara M, Kubota T, Saito H. No increased risk of major congenital anomalies or adverse pregnancy or neonatal outcomes following letrozole use in assisted reproductive technology. Hum Reprod 2017;32:125–132.

Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010;1:41.

Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2018;89:251–268.

Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018b;110:364–379.

Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction (Oxford, England) 2018c;33:1602–1618.

Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BGA, Wong JLA, Norman RJ, Costello MF. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust 2011;6:565.

Tehraninejad ES, Nasiri R, Rashidi B, Haghighahi F, Ataie M. Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients. Arch Gynecol Obstet 2010;3:319–325.

Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2014;11:CD006105.

Tulandi T, Martin J, Al-Fadhli R, Kabli N, Forman R, Hikani J et al. Congenital malformations among 91 I newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 2006;85:1761–1765.

van Santbrink EJ, Donderwinkel PF, van Dessel TJ, Fauser BC. Gonadotropin induction of ovulation using a step-down dose regimen: single-centre clinical experience in 82 patients. Hum Reprod 1995;10:1048–1053.

van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev 2011;2:CD005354.

Walls ML, Hunter T, Ryan JP, Keelan JA, Nathan E, Hart RJ. In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes. Hum Reprod 2015a;30:88–96.

Walls ML, Ryan JP, Keelan JA, Hart R. In vitro maturation is associated with increased early embryo arrest without impairing morphokinetic development of useable embryos progressing to blastocysts. Hum Reprod 2015b;30:1842–1849.

Wang R, Kim BY, van Wely M, Johnson NP, Costello MF, Zhang H, Ng EHY, Legro RS, Bhattacharya S, Norman RJ et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ 2017;356:j138.

White DM, Polson DW, Kiddy D, Sagle P, Watson H, Gilling-Smith C, Hamilton-Fairley D, Franks S. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 1996;81:3821–3824.

Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of ovulation. J Clin Endocrinol Metab 1998;81:3984–3991.

Youssef MA, Van der Veen F, Al-Inany HG, Mohtar MH, Griesinger G, Nagi Mohsen M, Aboulfoutouh I, van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014;10:CD008046.

Zeinalzadeh M, Basirat Z, Esmailpour M. Efficacy of letrozole in ovulation induction compared to that of clomiphene citrate in patients with polycystic ovarian syndrome. J Reprod Med 2010;1–2:36–40.